Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"so this idiot who was complaining about his company getting squeezed out for 180 days just squeezed everyone out for much longer."
SAMSA, IF your hypotesis comes true, then I think you just discovered a wonderful strategy for the Pharma to extend their exclusivity period. Just pay an "idiot" who files a complain pretending to ask for something in favour of competition...
what you get is in fact the opposite. Brilliant.
Hope this is not the case, anyway FDA si a jungle where only the gorillas rule.
So after Focalin mess we are about to have a Seroquel debacle?
Odidi better think to sell everything....ipci is too small to survive generics war.
Hope to be wrong but we risk a free fall if company announces some kind of setback.
This FDA mess sounds unreal.
As long as Lupin is in the same boat we know it is not something related to IPCI.
If there is a general lack of approvals then we know it's just the FDA.
Which is the value of a week of delay for all the companies having their approvals dispersed in a black hole ??
Unbelievable
FDA is the synthesis of corruption and burocracy.
For me, citizen of south Europe, feels like home.
Disgusting
The Canadian manufacturer of OxyContin has agreed to pay C$20m (US$14.5m/£11.3m) to settle a long-standing class-action lawsuit.
The claim centred on allegations that Purdue Pharma Canada used deceitful marketing practices for the powerful prescription painkiller.
The proposed resolution brings to a close a legal battle launched in 2007.
Purdue says it makes no admissions of liability by resolving the class action.
A spokeswoman for the pharmaceutical company said on Tuesday the complaints "stemmed from marketing activities that allegedly occurred primarily between 1996 and 2001".
ADVERTISEMENT
The multi-million dollar nationwide settlement includes $2m(US$1.5m/£1.1m) compensation for provincial health authorities. The settlement still needs to receive approval in Canadian courts.
America's new heroin addicts
Lawyer Ray Wagner, whose Halifax-based firm partly oversaw the class action, said on Tuesday that if everything proceeds as planned, the settlement should be finalised by mid-2018 or early 2019.
"The litigation has gone on for 10 years," Mr Wagner said.
"In no way is it going to resolve the harm to individuals so horribly affected by (the drug) but it's at least some resolution and, if approved by the court, some comfort."
He said the lawsuit currently has about 2,000 claimants who say they became addicted to OxyContin after being prescribed the narcotic.
They represent "a real spectrum" of people ranging from labourers to business owners, retired police officers, and athletes.
The class action and resolution is being overseen by a consortium of four law firms, including Mr Wagner's, who filed claims against Purdue in various Canadian jurisdictions a decade ago.
Behind the United States, Canada is the second-largest per capita consumer of opioids.
Canada, like the US, is struggling to get a handle on soaring rates of opioid addiction and abuse.
Health Canada says the opioid crisis is driven both by the emergence of fentanyl and other powerful illicit opioids as well as high levels of addiction to legal painkillers.
The federal health agency says the addictions "have been caused, in part, by inappropriate prescribing practices and poor education about the risks associated with opioids".
What's killing white middle-aged American women?
In 2007, Purdue and three of its top American executives pleaded guilty in Federal Court in Virginia to "misbranding" by falsely claiming OxyContin was less addictive and less subject to abuse than other pain medications,
They agreed to pay over US$600m in fines and other payments.
Purdue Pharma stopped selling OxyContin in Canada in 2012.
Angelo, Samsa, Wimus, Cysonic, Amigo Mike, Doog and whoever might like the idea...
Ipci board members you can contact me fabiustherabius@gmail.com
I will also serve as a connector in case some of u would prefer to have just selective contacts and skip the others.
Let's see now what the Orange Book is telling
I believe that the problem would if other companies will have final approval being IpCi the only one stalled.
As far as the same fate is shared between those waiting for final approval then we don't have a company specific issue, but and FDA one instead.
".. is there a way to exchange private eMail addresses with posters here without disclosing it to everyone on this message board."
Would be very nice indeed.
I think it can only be made if one of those who have PM functions starts sending his email to you and others making the central connector
Sprot,
Why the smile ????
Happy to see 1.75 ???
What the f. is wrong with u ?
wimike,
just to add...
in M&A transaction you can also have a component paid in shares of the buying co.
Better an all-cash deal, but not so uncommon the combination of both
Angelo,
mi hai fatto sorridere.
This quotes from the Divina Commedia seems particularly appropriated to the recent IPCI behaviour.
I'm not giving up, I will stay here and hope to meet many of this board in person, maybe beginning next year ?
Now IPCI needs partnering (but with Purdue lawsuit pending wouldn't be easy to close a nice deal...unless Purdue will b the partner).
Odidi has to deliver, and big time.
FDA has to deliver as well; one of the 2 ANDAs partnered with MK before July ??
Per Aspera ad Astra
strongly true,
"Everyone should research P/E. The standard P/E for IPCI sector is 50-60. The forward P/E for IPCI sector is 20-30. "
I have been saying this many many times, when I saw valuing IPCI using a P/E that is similar to that of PFE
Tek,
share price was @ 3 in february, now heading with good speed towards 1.5.
The cash issue was there in feb and here now.
This stock is being destroyed with 300K usd of trading volume per day, most likely 2 third of which between same Group of accounts.
Due diligence here is without value at the moment; stock is being played and the company is in someway make it possible (without giving IR and updates reassuring the market).
We simply have NO BUYERS.
Wimus, the stock is hostage of the group who subscribed the new shares issue.
Some of them are writing here about a fair valuation of the company since there is too much uncertainty.
Samsa well outlined how the positives are deemed as already priced in while the negatives seems to be the only driver.
I wrote here more than once that this stock is sick, there is a disconnect between co developments and price action.
This is going to continue unless company decide to make a major change.
Shorting ipci is like an ATM, so why should they stop ? Fundamentals are not considered anymore.
Odidi has the responsibility of letting the stock being played for so long, here the damage is reputation.
Ipci can now be considered a nice story with a broken stock.
For the first time after 3yrs of being invested I feel stuck.
Hope to see all this mess ending soon, maybe thanks to Odidi getting frustrated and logorated.
I think you could be right. You were right from the beginning in terms of share price evolution
Zoomik you will find more than one on this board ready to say ipci is currently fairly valued.
Saddest stock I have ever hold (sad considering the potentials and the reality)
Glty
Aegis cut tp to 2$ - HOLD
I agree with Samsa when he says now it is more difficult to sign an Agreement on Rexista, unless it included a discount in the terms due to litigation uncertainties.
I agree with Amigo when he says that at the moment the pipeline looks stalled; hence no need for an institutional buyer to step in. I wrote it looks, since we cannot know anything of what is going on with the company, thanks to their magnificient PR.
it is now time for positive surprises; it is more than a year they are talking about Regabatin partnership...why so long, nobody interested in this NDA ?? it seems strange
even a new ANDA approval, one of those in Mallinkrodt Agreement, would help.
I believe the long term investment horizon (exit strategy) has moved from whithin next 2 yrs to from 3 to 5 yrs.
GLTA
Offering
The July offering was the mother of all mistakes.
If they plan a second one, they better do it with a strategic partner...but then Odidi will be able to understand that he has to concede some company control ?
otherwise the only one avaible for a new offering will be asking for warrants and the like....really don't wanna see it
Yes, but
we are down big on big volume, on something which should have been already factored in.
...and...just now we could have been in the opposition situation, since the suit was announced this morning which was the very last minute for announcing it (whithin the legal terms).
and we would have had a clearer situation as well !
I just strongly believe that over the last two years Odidi proved he needs to be in the Lab; unfortunately Della Penna has been nothing more than a comprimary. I still have some hope he was put there by TEVA (which is about to sell the woman business for around 2bln).
Samsa,
manipulation will be the king here until some institutional buyer comes in, which is not happening until company clarifies its strategy.
On this point I think Amigo was right several times.
If we don't recover in very short time from here we are likely going to sit below 2 for a while.
Now prepare for the next pain: need for cash...and let the new shares issue debate begin. Sad.
PS
I added some at 1.93.
OK doog,
but would you consider IPCI stronger or weaker at negotating table with a potential partner HAVING now a lwasuit pending over is head (even if likely to be in the near term dimissed) ?
I am a long investor, and you know, but this "expected outcome" as Odidi called it, makes just the company weaker when it needed to be stronger (negotation phase)
Beachguy....??
Maybe we will have some nice surprise in the upcoming results, but honestly this is a setback.
I am long with a big amount of shares and I don't like being where we were 1 year ago, do you ?
We all hope for the best, but would you call Odidi a good negotiator ? I think many here pointed out that waiting too long for the partnership (=cash+legal resources) would have exposed the company to many risks.
"and Grünenthal GmbH "...ok, they are out of potential partner list.
I would say stock will be in the hands of the shorters and manipulators for many months to come.
Max merit to Sprot, he simply and multiple times repeated that there was still a looooottt of time before arriving to gain.
Poor Odidi likely didn't get that he needed to partner with a big co. when filing ...instead oof waiting till the last moment. A good scientis is often a very bad negotiator.
GLTA...we will be needing a lot of it !
Doog,
likely Odidi science will make all of us very happy, but the gaming of this Group would have been less easy if the management would have been able to give some key info probably attracting some important investor.
to name a few (without any specific order):
- status of pending ANDAs
- deadline for possible lawsuit by Purdue (we had to calculate by ourself the last possible day....having an Analyst writing very 3 months theat they will be sued)
- their strategy on Rexista+Prodras (not just the "plug and play" expression used by DellaPenna)
- their plan for the Odidi convertible
- etc.
Once the management understands that their stock is being played it should take necessary action to give confidence to their shareholders; but they don't care about us, with the risk of being played themself by the manipulators.
Lastly, their lack of PR and clarity has made them an unreliable company for a potential investor.
GLTY
I am just disgusted due to price action.
But I can say the big responsability for what is happening goes to a managment acting like a private co (hence my delisting comment).
everybaody here is trying with immense effort to understand which are the company's plan since they are not saying a word.
GLTA
something bad...on low volume...last time I wrote I said I was expecting something like a flash crash...don't know if flas...but crash is here...
this stock should be deliste
Sprot,
it wasn't intended as a personal attack, just the attitude of many here that a stock can JUST go up or down...I was just adding the trading range scenario (which for a longer is a hold situation).
Now I am expecting a pilotated crash...likely to hit 1.6-1.7 in a single day. I will then buy more.
When we will be around 1.6-1.7 I'm sure there will be someone saying it is fairly valued.
I have a long time horizon, so I can wait...and hope one day we will celebrate together !
GLTY
He is very demanding with himself. LoL
And why would you sell?
You belong to the list of buy or sell...Hold doesn't belong to you
Amigo,
You probably forgot that a stock can stay sidelines.
If there is no buying pressure it doesn't have to go indefinitely down.
But I do hope that we see a crash in the price so many here will finally be satisfied.
No Amigo,
I'm not. I believe hard facts as you call them are not part of the baby biotech world.
Where are hard facts of Tobira, Cnat, genfit...To name a few...If they where known before partnership or buyout why didn't very body jump on board and push the price through the roof?
BMY got hammered because failed a p3 on its leading development drug...The company was up more than 20% since the beginning of the year, then down 30% in a few days. Uncertainty is there Amigo, even for the big ones.
And the market was previously expecting a success based on what? Hard facts?
My wishful thinking, as you call it, is Prodras is going to work, rebating will be partnered and Rexista will have a decent success.
When you will know if they are a success or not ... Market will adjust immediately...Based on the then known hard facts. It's not going to give you hard facts before.
We are all making DD but then you have by definition to discount future...and uncertainty is where future is.
Amigo,
They are not buying until they are.
Or maybe they are not.
My point is: you can infer whatever you want about Rexista or Prodras, but only an industrial partner will have access to info which will allow them to make or not a move.
Wishful thinking? Podras, Rexista, Regabating.
And where are known hard facts of CAN'T or
Amigo,
your analysis is more than welcome (at least to me). And I agree on many of the defincies you often outlined and in the company ability to communicate a clear path (if not just ignoring to PR drugs filing in Canada).
I just diverge when it comes to final valuation, but not beacause of your process, methods and the like, but just because I belive that when it comes to baby biotech there is a BIG component of unexplicabale or just not known.
Sometimes the speculation prefers to see this component instead of the natural issues and uncertainties other times (like for IPCI) we just get the attention on what is realized.
But I believe that the major part of the value is potentially in this uncertain component indeed.
You give zero to this element I give much more; if the value is there, it could then happen something like for CNAT (which I am mentioning because I would say that they needed cash and they still have a lot to prove given their early stage); if it is not there the stock will go on in these sidelines for years to come.
That's the baby biotech to me; when the value is unleashed and uncertainties cleared...well it is just too late for us small investors.
Only those professional players who have preferential access to the technology/science of a baby biotech can make an accurate valuation....
the only way for us to make much money is to take a lot of risk !
Amigo,
a comment just on your last sentence
"Stock price action pretty much tells you what's going on too. "
I respect your position but I belong (and likely many Others here) to the party "Market is NOT Always right", but I am well aware of those sticking to the market efficency hypotesis (shares prices discounts everything).
Hence for you IPCI is correctly priced, to me instead it looks like IPCI belogns to the darks side of biotechs LoL (or hidden gems); nobody likes them, they are very small and the management often is not prepared for a listed co experience, and they have pipelines that are often misunderstood. These are the biotechs which make unbelievable gains when took over or partnered with big pharmas.
for them the price is discounting just the bads and uncertainties, then...all of a sudden....
I'm not saying you are wrong and I'm right, just consider the possibility that market is not always right.
My opinion is Odidi is not a manger, but if he is a good scientist, then IPCI will make it all of a sudden. JMHO
Amigo,
could you help me here: post #25293 fo Numbers refers to CII drugs under the DEA realm, which could potentially be produced in Canada and then imported in US.
it is or it is not like saying "class II narcotic/controlled substance " as you referred to for Rexista ?
TIA
remarkable finding kfcyahoo,
" to be in a position to receive final approvals for ANDAs and NDAs and to permit manufacturing of drug products intended for commercial sales in the United States after any such approvals."
Concerning the lack of company communication/PR; I think Odidi is taking markets behavious as something personal, without recognizing he is part of the problem.
WZ 4 president !
Don't quit !
Sorry if I disturbed you.
Exactly Wimus,
when it comes to comparisons IPCI is the loser against almost every other biotech. LoL
"Also for comparison, COLL is burning $25M a quarter. They also just instituted a $60M ATM. They are still trading at $16. Do you know what their last quarter sales were for Xtampza? Less than $2M... IPCI hopefully does $2M in sales 2017Q1 or 2017Q2. Maybe someday IPCI will get a proper valuation."
What I've been trying to say many times, receiving comments that IPCI is fairly valued based on earnings, based on uncertainties, based on...
I never advocated for the share price to be Flying, but to be around 4.5 - 5$ would be in line with Others.
But this is a neverending debate.
This stock right now is sick, as it has been over the last 9 months.
Hope for the firday tradition to be renovated today.
Samsa,
do you think a possible yearly fee could be higher then the profit potentially coming in by Glucophage ?
I'm not sure to understand, but are we saying that rest of the ANDAs (out of Focalin and MKN deal) are better to be adandoned ?
I do believe a LOW profit it's Always better than nothing at all.
This is the craziest stock I ever invested in; shares price is nonsense, pessimism mounting from every angle after 9months of positive developments, small cap biotech considered like it was a value blue-chip (P/E more important than growth prospects).
Honestly, this company-stock is an uniqum. Hope it will be an uniqum when reward for an investor will come.
GLTA
you can have an increasing mkt cap but a dreasing share price, I think you know...
so pure comparison of just mkt cap is nonsense